Cargando…

Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors

BACKGROUND: Thyroid dysfunction is among the most common autoimmune diseases and immune checkpoint inhibitor (ICI)-induced immune-related adverse events (irAE). We determined the association between longitudinal thyroid function and clinical outcomes in patients treated with ICI. METHODS: We identif...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Itzstein, Mitchell S., Gonugunta, Amrit S., Wang, Yiqing, Sheffield, Thomas, Lu, Rong, Ali, Sadia, Fattah, Farjana J., Xie, Donglu, Cai, Jennifer, Xie, Yang, Gerber, David E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308834/ https://www.ncbi.nlm.nih.gov/pubmed/35072744 http://dx.doi.org/10.1007/s00262-022-03151-2

Ejemplares similares

Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
por: von Itzstein, Mitchell S., et al.
Publicado: (2022)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report
por: Gonugunta, Amrit S., et al.
Publicado: (2022)

Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy
por: von Itzstein, Mitchell S., et al.
Publicado: (2022)

Humoral and cellular correlates of a novel immune-related adverse event and its treatment
por: Gonugunta, Amrit S, et al.
Publicado: (2021)

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
por: Ahmed, Murtaza, et al.
Publicado: (2021)

Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon
por: Khan, Shaheen, et al.
Publicado: (2020)

T-cell tolerant fraction as a predictor of immune-related adverse events
por: Ostmeyer, Jared, et al.
Publicado: (2023)

Immune checkpoint inhibitors for patients with pre-existing autoimmune diseases
por: Maeda, Osamu
Publicado: (2023)

Assessment of Thyroid Dysfunction Among Pregnant Women With Pre-Existing Diabetes Mellitus or Gestational Diabetes Mellitus
por: Alotaibi, Eman A, et al.
Publicado: (2023)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Regional Anaesthesia in the Patient with Pre-Existing Neurological Dysfunction
por: Bajaj, Pramila
Publicado: (2009)

Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?
por: von Itzstein, Mitchell S., et al.
Publicado: (2020)

Circulating mitochondrial DNA as a biomarker for lung cancer screening
por: von Itzstein, Mitchell S., et al.
Publicado: (2022)

Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
por: Crittenden, Marka R., et al.
Publicado: (2018)

Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
por: Alexander, Swetha, et al.
Publicado: (2021)

Comparison of outcomes from sepsis between patients with and without pre-existing left ventricular dysfunction: a case-control analysis
por: Ouellette, Daniel R, et al.
Publicado: (2014)

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
por: Gerber, David E., et al.
Publicado: (2022)

Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review
por: El Sabbagh, Rawaa, et al.
Publicado: (2020)

Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection
por: von Itzstein, Mitchell S., et al.
Publicado: (2020)

The impact of sacrospinous ligament fixation on pre-existing nocturia and co-existing pelvic floor dysfunction symptoms
por: Himmler, Maren, et al.
Publicado: (2020)

Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease
por: Chau, Charlene Y. C., et al.
Publicado: (2020)

Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
por: Olsson-Brown, Anna, et al.
Publicado: (2020)

Transient Thyroiditis Followed by Exacerbation of Hypothyroidism After Immune Checkpoint Inhibitor Therapy (Nivolumab and Ipilimumab) in a Patient With Pre-existing Autoimmune Hypothyroidism: A Case Report
por: Hayakawa, Guy, et al.
Publicado: (2023)

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
por: Martinez Chanza, Nieves, et al.
Publicado: (2020)

Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors
por: Kurimoto, Chiaki, et al.
Publicado: (2020)

Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction
por: Zhang, Qin, et al.
Publicado: (2023)

Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report
por: Edmondson, Shelby, et al.
Publicado: (2022)

Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy
por: Lusa, Amanda, et al.
Publicado: (2022)

Impact of Pre-existing Kidney Dysfunction on Outcomes Following  Transcatheter Aortic Valve Replacement
por: Ifedili, Ikechukwu A., et al.
Publicado: (2017)

Pre-existing weakness is critical for the occurrence of postoperative cognitive dysfunction in mice of the same age
por: Tang, Yujie, et al.
Publicado: (2017)

No calcitonin change in a person taking dulaglutide diagnosed with pre‐existing medullary thyroid cancer
por: Sherman, S. I., et al.
Publicado: (2018)

Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study
por: Noseda, Roberta, et al.
Publicado: (2020)

Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data
por: Calvo, Virginia, et al.
Publicado: (2021)

Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
por: Lopez-Olivo, Maria A., et al.
Publicado: (2023)

Genetic Basis of Chromate Adaptation and the Role of the Pre-existing Genetic Divergence during an Experimental Evolution Study with Desulfovibrio vulgaris Populations
por: Shi, Weiling, et al.
Publicado: (2021)

Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?
por: von Itzstein, Mitchell S., et al.
Publicado: (2020)

SAT-473 Thyroid Dysfunction in a Patient with Malignant Melanoma Treated with Immune Checkpoint Blockade
por: Gupta, Shaveta, et al.
Publicado: (2020)

Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
por: Baek, Han-sang, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management
por: Zhan, Ling, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u1r642969g9g6orsp3s07u33vg